Top

Published in:

01-12-2009

An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis

Authors: Michael Valentino, John Frelinger

Published in: Immunologic Research | Issue 2-3/2009

Abstract

The identification and characterization of epitopes is essential for modern immunologic studies. Here, we describe a novel methodology we have developed to identify T cell epitopes exploiting the phenomenon of cross presentation. Particulate antigens, in the form of beads, are very effective in delivering exogenous antigen to both the class I and class II pathways. We will review our efforts to screen entire genomes of pathogens for T cell epitopes taking advantage of the advances in genomics using Francisella tularensis as a model. By automating aspects of this technology we will be able to functionally screen the entire genome of F. tularensis for T cell epitopes. This technology should be applicable not only to F. tularensis, but also to many other pathogens as well.

Harding CV, Leyva-Cobian F, Unanue ER. Mechanisms of antigen processing. Immunol Rev. 1988;106:77–92.CrossRefPubMed

Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol. 2008;8:607–18.CrossRefPubMed

Berzofsky JA, Brett SJ, Streicher HZ, Takahashi H. Antigen processing for presentation to T lymphocytes: function, mechanisms, and implications for the T-cell repertoire. Immunol Rev. 1988;106:5–31.CrossRefPubMed

Reis e Sousa C, Germain RN. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med. 1995;182:841–51.CrossRefPubMed

Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA. 1993;90:4942–6.CrossRefPubMed

Rock KL, Clark K. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol. 1996;156:3721–6.PubMed

Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG. IL-3-mediated enhancement of particulate antigen presentation by macrophages. J Immunother. 1998;21:205–10.CrossRefPubMed

Storozynsky E, Woodward JG, Frelinger JG, Lord EM. Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells. Immunology. 1999;97:138–49.CrossRefPubMed

Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev. 2005;207:166–83.CrossRefPubMed

10.

Shen L, Rock KL. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol. 2006;18:85–91.CrossRefPubMed

11.

Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol. 2001;1:126–34.CrossRefPubMed

12.

Levine B, Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol. 2007;7:767–77.CrossRefPubMed

13.

Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol. 1997;158:2723–30.PubMed

14.

Yeh KY, McAdam AJ, Pulaski BA, Shastri N, Frelinger JG, Lord EM. IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes. J Immunol. 1998;160:5773–80.PubMed

15.

Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol. 1994;153:4925–33.PubMed

16.

Bevan MJ. Antigen recognition. Class discrimination in the world of immunology. Nature. 1987;325:192–4.CrossRefPubMed

17.

Turner MJ, Abdul-Alim CS, Willis RA, Fisher TL, Lord EM, Frelinger JG. T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes. J Immunol Methods. 2001;256:107–19.CrossRefPubMed

18.

Sanderson S, Shastri N. LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol. 1994;6:369–76.CrossRefPubMed

19.

Sjostedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann NY Acad Sci. 2007;1105:1–29.CrossRefPubMed

20.

Chen W, Shen H, Webb A, KuoLee R, Conlan JW. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine. 2003;21:3690–700.CrossRefPubMed

21.

Conlan JW, Chen W, Shen H, Webb A, KuoLee R. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog. 2003;34:239–48.CrossRefPubMed

22.

Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect. 2003;5:135–42.CrossRefPubMed

23.

Twine SM, Shen H, Kelly JF, Chen W, Sjostedt A, Conlan JW. Virulence comparison in mice of distinct isolates of type A Francisella tularensis. Microb Pathog. 2006;40:133–8.CrossRefPubMed

24.

Oyston PC, Sjostedt A, Titball RW. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat Rev Microbiol. 2004;2:967–78.CrossRefPubMed

25.

Eigelsbach HT, Downs CM. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol. 1961;87:415–25.PubMed

26.

Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immunity to Francisella. Ann NY Acad Sci. 2007;1105:284–324.CrossRefPubMed

27.

Griffin KF, Oyston PC, Titball RW. Francisella tularensis vaccines. FEMS Immunol Med Microbiol. 2007;49:315–23.CrossRefPubMed

28.

Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med. 1961;107:702–14.PubMed

29.

Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S. Tularemia vaccine study. I. Intracutaneous challenge. Arch Intern Med. 1961;107:689–701.PubMed

30.

Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun. 1996;64:3288–93.PubMed

31.

Yee D, Rhinehart-Jones TR, Elkins KL. Loss of either CD4⁺ or CD8⁺ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J Immunol. 1996;157:5042–8.PubMed

32.

Conlan JW, Sjostedt A, North RJ. CD4⁺ and CD8⁺ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect Immun. 1994;62:5603–7.PubMed

33.

Elkins KL, Rhinehart-Jones T, Nacy CA, Winegar RK, Fortier AH. T-cell-independent resistance to infection and generation of immunity to Francisella tularensis. Infect Immun. 1993;61:823–9.PubMed

34.

Rhinehart-Jones TR, Fortier AH, Elkins KL. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun. 1994;62:3129–37.PubMed

35.

Sjostedt A, Sandstrom G, Tarnvik A. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infect Immun. 1992;60:2855–62.PubMed

36.

Golovliov I, Ericsson M, Akerblom L, Sandstrom G, Tarnvik A, Sjostedt A. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis. Vaccine. 1995;13:261–7.CrossRefPubMed

37.

Lee BY, Horwitz MA, Clemens DL. Identification, recombinant expression, immunolocalization in macrophages, and T-cell responsiveness of the major extracellular proteins of Francisella tularensis. Infect Immun. 2006;74:4002–13.CrossRefPubMed

38.

McMurry JA, Gregory SH, Moise L, Rivera D, Buus S, De Groot AS. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine. 2007;25:3179–91.CrossRefPubMed

39.

Sjostedt A, Tarnvik A, Sandstrom G. The T-cell-stimulating 17-kilodalton protein of Francisella tularensis LVS is a lipoprotein. Infect Immun. 1991;59:3163–8.PubMed

40.

Eyles JE, Unal B, Hartley MG, Newstead SL, Flick-Smith H, Prior JL, et al. Immunodominant Francisella tularensis antigens identified using proteome microarray. Crown Copyright 2007 Dstl. Proteomics. 2007;7:2172–83.CrossRefPubMed

41.

Huntley JF, Conley PG, Hagman KE, Norgard MV. Characterization of Francisella tularensis outer membrane proteins. J Bacteriol. 2007;189:561–74.CrossRefPubMed

42.

Havlasova J, Hernychova L, Halada P, Pellantova V, Krejsek J, Stulik J, et al. Mapping of immunoreactive antigens of Francisella tularensis live vaccine strain. Proteomics. 2002;2:857–67.CrossRefPubMed

43.

Murthy T, Rolfs A, Hu Y, Shi Z, Raphael J, Moreira D, et al. A full-genomic sequence-verified protein-coding gene collection for Francisella tularensis. PLoS ONE. 2007;2:e577.CrossRefPubMed

44.

Larsson P, Oyston PC, Chain P, Chu MC, Duffield M, Fuxelius HH, et al. The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet. 2005;37:153–9.CrossRefPubMed

45.

Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, Hernandez JE, et al. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol. 2008;82:652–63.CrossRefPubMed

46.

Doolan DL, Southwood S, Freilich DA, Sidney J, Graber NL, Shatney L, et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci USA. 2003;100:9952–7.CrossRefPubMed

47.

Davies DH, Liang X, Hernandez JE, Randall A, Hirst S, Mu Y, et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci USA. 2005;102:547–52.CrossRefPubMed

48.

Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187:265–70.CrossRefPubMed

49.

Lee SY, Jeoung D. The reverse proteomics for identification of tumor antigens. J Microbiol Biotechnol. 2007;17:879–90.PubMed

50.

Gunawardana CG, Diamandis EP. High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett. 2007;249:110–9.CrossRefPubMed

Title: An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis
Authors: Michael Valentino
John Frelinger
Publication date: 01-12-2009
Publisher: Humana Press Inc
Published in: Immunologic Research / Issue 2-3/2009
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-009-8103-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2009

Xenopus, a unique comparative model to explore the role of certain heat shock proteins and non-classical MHC class Ib gene products in immune surveillance

The emerging field of osteoimmunology

Two pathways of costimulation through CD28

T helper cytokine patterns: defined subsets, random expression, and external modulation

The platelet as an immune cell—CD40 ligand and transfusion immunomodulation

Regulation of immunity at tissue sites of inflammation